--- title: "First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/295708147.md" description: "In San Diego on August 12, 2026, First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a biotech company focusing on antibody therapeutics for autoimmune and inflammatory diseases, announced their financial results for the second quarter of 2026 ending on June 30. The company also shared a general business update." datetime: "2026-08-12T20:29:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295708147.md) - [en](https://longbridge.com/en/news/295708147.md) - [zh-HK](https://longbridge.com/zh-HK/news/295708147.md) --- # First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update In San Diego on August 12, 2026, First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a biotech company focusing on antibody therapeutics for autoimmune and inflammatory diseases, announced their financial results for the second quarter of 2026 ending on June 30. The company also shared a general business update. ### Related Stocks - [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md) ## Related News & Research - [Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases](https://longbridge.com/en/news/295529846.md) - [Baseball-MLB owners unanimously approve sale of San Diego Padres](https://longbridge.com/en/news/296137237.md) - [Mineralys Therapeutics publishes corporate presentation on lorundrostat for uncontrolled, resistant hypertension and cardiorenal diseases](https://longbridge.com/en/news/295607030.md) - [Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab program](https://longbridge.com/en/news/295789100.md) - [11:16 ETBIOSAPIEN - THE REVOLUTIONARY CANCER PLATFORM DEVELOPER - NOMINATED AS "BEST STARTUP" IN THE 2026 PRIX GALIEN USA AWARDS](https://longbridge.com/en/news/295952681.md)